The Role of Sphingolipids Metabolism in Cancer Drug Resistance

作者：Marina Bataller, Almudena Sánchez-García, Yoelsis Garcia‐Mayea, Cristina Mir, Isabel Rodríguez, Matilde E. Lleonart · 发表于：Frontiers in Oncology · 年份：2021 · DOI：10.3389/fonc.2021.807636 · 被引用次数：56 · 研究领域：Sphingolipid Metabolism and Signaling、Lipid Membrane Structure and Behavior、Endoplasmic Reticulum Stress and Disease

Drug resistance continues to be one of the major challenges to cure cancer. As research in this field evolves, it has been proposed that numerous bioactive molecules might be involved in the resistance of cancer cells to certain chemotherapeutics. One well-known group of lipids that play a major role in drug resistance are the sphingolipids. Sphingolipids are essential components of the lipid raft domains of the plasma membrane and this structural function is important for apoptosis and/or cell proliferation. Dysregulation of sphingolipids, including ceramide, sphingomyelin or sphingosine 1-phosphate, has been linked to drug resistance in different types of cancer, including breast, melanoma or colon cancer. Sphingolipid metabolism is complex, involving several lipid catabolism with the participation of key enzymes such as glucosylceramide synthase (GCS) and sphingosine kinase 1 (SPHK1). With an overview of the latest available data on this topic and its implications in cancer therapy, this review focuses on the main enzymes implicated in sphingolipids metabolism and their intermediate metabolites involved in cancer drug resistance.